PS1

DEVICE2 trials

Sponsors

Neuromod Devices Ltd., Pharmasaga Co. Ltd.

Conditions

TinnitusType II Diabetes

Phase 1

Safety, Pharmacokinetics, and Food Effect of PS1 in Subjects

CompletedNCT05176210

Pharmasaga Co. Ltd.Type II Diabetes

Start: 2023-12-22End: 2026-06-05Updated: 2026-07-07

Unknown Phase

Treatment Evaluation of Neuromodulation for Tinnitus (TENT-A)

CompletedNCT02669069

Neuromod Devices Ltd.Tinnitus

Start: 2016-06-27End: 2019-01-30Updated: 2024-12-20

Related Papers

Combining sound with tongue stimulation for the treatment of tinnitus: a multi-site single-arm controlled pivotal trial.

2024-08-196 citations

Feasibility of deep learning to predict tinnitus patient outcomes

Intelligence-Based Medicine2024-01-011 citations

Bi-modal stimulation in the treatment of tinnitus: a study protocol for an exploratory trial to optimise stimulation parameters and patient subtyping

BMJ Open2017-10-0119 citations